iA Global Asset Management Inc. Increases Position in Zoetis Inc. $ZTS

iA Global Asset Management Inc. raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 798.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,327 shares of the company’s stock after purchasing an additional 42,059 shares during the period. iA Global Asset Management Inc.’s holdings in Zoetis were worth $5,595,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Global Wealth Strategies & Associates bought a new position in Zoetis during the fourth quarter valued at approximately $25,000. Prosperity Bancshares Inc purchased a new position in shares of Zoetis during the fourth quarter worth approximately $25,000. Lodestone Wealth Management LLC bought a new stake in shares of Zoetis in the 4th quarter worth approximately $30,000. KERR FINANCIAL PLANNING Corp purchased a new stake in shares of Zoetis in the 3rd quarter valued at $31,000. Finally, Holos Integrated Wealth LLC purchased a new stake in shares of Zoetis in the 4th quarter valued at $32,000. Institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In related news, Director Michael B. Mccallister acquired 3,000 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Paul Bisaro bought 2,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have purchased 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by company insiders.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: One recent note suggested Zoetis’ index shift could reinforce its competitive moat in companion-animal health, which supports the long-term investment case. Zoetis (ZTS) Index Shift: A Harbinger for Its Competitive Moat in Companion-Animal Health?
• Neutral Sentiment: Barclays cut its price target on Zoetis to $85 from $136 and kept an equal-weight rating, signaling a more cautious valuation view but not a bearish downgrade. Barclays price target cut on Zoetis
• Neutral Sentiment: TD Cowen lowered its target to $104 from $150 while maintaining a buy rating, reflecting softer near-term expectations while still seeing upside from current levels. TD Cowen price target cut on Zoetis
• Neutral Sentiment: Multiple firms reminded investors about the July 27 deadline to join the Zoetis securities class action, keeping legal uncertainty in focus for shareholders. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action
• Neutral Sentiment: Analyst commentary also highlighted that stabilization in Zoetis products may still be several quarters away, which adds to the view that fundamentals could remain challenged in the near term. This analyst thinks stabilization for Zoetis’ products could be several quarters away
• Negative Sentiment: The series of class-action notices may raise investor concern about alleged misstatements tied to product adoption, adding a legal overhang to the shares. ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL

Zoetis Stock Up 0.9%

Shares of NYSE:ZTS opened at $72.48 on Thursday. The stock’s 50-day moving average is $85.77 and its 200 day moving average is $109.95. The company has a market cap of $30.39 billion, a PE ratio of 12.02, a P/E/G ratio of 1.12 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a 1 year low of $71.47 and a 1 year high of $161.77.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter last year, the business posted $1.48 EPS. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is presently 35.16%.

Analysts Set New Price Targets

ZTS has been the subject of several analyst reports. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Argus reiterated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Morgan Stanley restated an “overweight” rating and set a $115.00 target price on shares of Zoetis in a report on Friday, May 15th. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, JPMorgan Chase & Co. decreased their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and a consensus price target of $126.92.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.